Mirai is an artificial intelligence (AI) breast cancer risk assessment tool developed by researcher Regina Barzilay, faculty lead for AI at the MIT Jameel Clinic, the epicentre of AI and healthcare at the Massachusetts Institute of Technology (MIT). Invented in 2020, Mirai uses a noninvasive deep learning system to detect breast cancer in mammograms up to five years before the cancer is detectable with current techniques.

In 2023, the MIT Jameel Clinic announced that Mirai would undergo clinical trials at the UMass Chan Medical School in Worcester, Massachusetts, United States, focused on women who are at high risk of breast cancer. Additionally, through the Jameel Clinic AI Hospital Network, Mirai will be deployed through partner hospitals around the world in order to empower healthcare systems at a global scale. One of the partnering hospitals in the network to deploy Mirai through a partnership with the MIT Jameel Clinic is the King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Saudi Arabia.